GENE ONLINE|News &
Opinion
Blog

2023-01-06| Asia-PacificLicensing

Following Amgen, Hummingbird Jumps Onto Synaffix’s ADC Platform In $150 Million Licensing Deal

by Joy Lin
Share To

Singapore-based Hummingbird Bioscience and Synaffix have entered into an antibody-drug conjugate (ADC) licensing agreement. The deal will enable Hummingbird Bio to combine its Rational Antibody Discovery (RAD) platform with Synaffix’s ADC development technologies to generate an ADC candidate. 

Synaffix’s offerings include their proprietary GlycoConnect and HydraSpace technologies as well as their toxSYN linker-payloads. The company is eligible to receive up to $150 million, including an undisclosed upfront payment and milestones, plus royalties on net sales. 

This is Synaffix’s second deal of the day, after a similar licensing agreement with Amgen which could earn the company up to $2 billion in milestones.

Related Article: A Force To Be Reckoned With – BioBetter Biologics

From RAD Antibody Discovery To ADC

Hummingbird Bio’s RAD platform is designed to discover antibodies against hard-to-target epitopes, the part of an antigen that the immune system recognizes. The model is driven by computational and systems biology. 

The company’s clutch includes HMBD-001, a humanized antibody that targets an epitope of HER3, and HMBD-002, which targets VISTA, an immune regulatory receptor. Both programs are currently in Phase 1 studies. 

In the case of the Synaffix deal, antibodies generated by RAD will be put through Synaffix’s GlycoConnect, a conjugation technology that enables payload attachment to the native antibody glycan. Next, HydraSpace, a highly polar spacer technology, will further enhance the therapeutic index, particularly with hydrophobic payloads. Finally, the linker-payload system toxSYN will be used to attach Synaffix’s toxic payloads such as SYNtecan E or SYNeamicin G.  

Synaffix has out-licensed its ADC technology to many companies in the past, including ADC Therapeutics, Innovent Biologics, Kyowa Kirin, and Genmab. Three programs from the various collaborations have entered Phase 1 development. 

“Hummingbird Bio’s RAD platform generates high-affinity antibodies against unique epitopes on hard targets, potentially unlocking novel mechanisms of action. We believe that, by combining Synaffix’s ADC technologies with our antibodies, we have the potential to create best-in-class ADCs,” said Piers Ingram, Ph.D., CEO and co-founder of Hummingbird Bio. 

“We are excited by the potential of this partnership and look forward to sharing additional updates on our ADC efforts throughout 2023.”

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Hummingbird Bioscience to Present Two Posters on Anti-HER3 and Anti-VISTA Antibody Therapeutics at American Association for Cancer Research (AACR) Meeting 2024
2024-03-06
Pharmaceutical Giants Expand Research and Manufacturing Capabilities, Fueling 2024 Innovation and Growth
2024-03-01
GeneOnline’s Pick – Top 10 Global Industry News Stories in 2023 (Part 2)
2024-01-15
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top